Six insiders at Nautilus Biotechnology, Inc. (NAUT) divested a significant number of shares on June 2, 2026, totaling approximately $65.09 million. Among the sellers were 10% owners Marc L. Andreessen and Benjamin A. Horowitz, each selling 4,615,974 shares at a price of $2.35 per share, valued at $10.85 million. Other entities, including Bio Fund Ii, L.P. Ah, Equity Partners Bio Ii, L.L.C. Ah, Horowitz Lsv Fund Ii, L.P. Andreessen, and Equity Partners Lsv Ii, L.L.C. Ah, also executed identical sales of 4,615,974 shares each.
These transactions represent a substantial outflow of capital from key individuals and affiliated entities within Nautilus Biotechnology. While insider selling can be attributed to various personal financial strategies such as diversification or tax obligations, the collective nature of these sales by multiple insiders may draw investor attention.
Nautilus Biotechnology, Inc. operates in the biotechnology sector, focusing on developing technologies for protein analysis. The company's stock performance and future catalysts will be closely watched following this significant insider divestiture.